CLYM19123 / AALL1731 / Angela Girvin
Basic Study Information
Purpose:
This phase III trial studies how well blinatumomab works in combination with chemotherapy
in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia
or B-lymphoblastic lymphoma with or without Down syndrome. Monoclonal antibodies,
such as blinatumomab, may induce changes in the body's immune system and may interfere
with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such
as vincristine, dexamethasone, prednisone, prednisolone, pegaspargase, methotrexate,
cytarabine, mercaptopurine, doxorubicin, cyclophosphamide, and thioguanine, work in
different ways to stop the growth of cancer cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Leucovorin decreases
the toxic effects of methotrexate. Giving monoclonal antibody therapy with chemotherapy
may kill more cancer cells. Giving blinatumomab and combination chemotherapy may work
better than combination chemotherapy alone in treating patients with B-ALL. This trial
also assigns patients into different chemotherapy treatment regimens based on risk
(the chance of cancer returning after treatment). Treating patients with chemotherapy
based on risk may help doctors decide which patients can best benefit from which chemotherapy
treatment regimens.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Angela Girvin
Study Contact Information
Study Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Email: tina_bowdish@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search